Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology - 1 Apr 2024

Balestrino R, Martone T, Toffoli M, Montanaro E, Fabbri M, Artusi C A, Romagnolo A, Zibetti M, Rizzone M, Goldwurm S, Lopiano L, Schapira A H V

Abstract excerpt

BACKGROUND: Levodopa-carbidopa intestinal gel infusion (LCIG) is a therapeutic option for advanced Parkinson disease (PD) patients with troublesome motor complications, unresponsive to conventional oral treatment. There is some evidence to suggest that the genetic background may influence the clinical presentation and rate of progression of PD. Whether the genetic background influences the outcome of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Drug Combinations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Levodopa

Share to Mutation

Share to Parkinson Disease

Source

Identifiers

PMID: 37926749
DOI: 10.1007/s10072-023-07173-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Levodopa-carbidopa intestinal gel infusion (LCIG) in Parkinson disease with genetic mutations.PMID 37926749Read ↗

Effects of GBA1 Variants in Patients With Parkinson's Disease and Levodopa-Carbidopa Intestinal Gel: A Nation-Wide, Multicenter, Longitudinal, "Real-World" Study. The EPIC Study.Semantic proximity Read ↗

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations.Semantic proximity Read ↗

Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease.Semantic proximity Read ↗

Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.Semantic proximity Read ↗

GBA-Associated Parkinson's Disease: Progression in a Deep Brain Stimulation Cohort.Semantic proximity Read ↗

Pharmacogenetics and levodopa induced motor complicationsSemantic proximity Read ↗

Clinical Utility of GBA Genotyping Prior to Deep Brain Stimulation: A Narrative Review.Semantic proximity Read ↗

Early motor response to dopamine replacement therapy in Parkinson's disease patients carrying GBA variants.Semantic proximity Read ↗

Effect of deep brain stimulation on early-onset Parkinson's disease with mutations in a Han Chinese Mainland population.Semantic proximity Read ↗

Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation.Semantic proximity Read ↗

Long-term motor and cognitive outcome of Deep Brain Stimulation in GBA-PD: the Italian PARKNET studySemantic proximity Read ↗

Short-and long-term responsiveness of deep brain stimulation on motor and cognitive outcomes in GBA vs. Non-GBA parkinson's disease: a systematic review and meta-analysis of observational studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.